Regulatory Effects of Fecal Microbiota Transplantation on Inflammatory Cytokines in a DSS-Induced Colitis Mouse Model

Trends in Immunotherapy

Article

Regulatory Effects of Fecal Microbiota Transplantation on Inflammatory Cytokines in a DSS-Induced Colitis Mouse Model

Downloads

https://doi.org/10.54963/ti.v10i1.1801
Liu, L., Xu, Y., Chen, D., Zhang, J., Zhang, A., & Bai, X. (2026). Regulatory Effects of Fecal Microbiota Transplantation on Inflammatory Cytokines in a DSS-Induced Colitis Mouse Model. Trends in Immunotherapy, 10(1), 174–188. https://doi.org/10.54963/ti.v10i1.1801
Volume 10, Issue 1 (March 2026): In Progress
Copyright (c) 2026 Li Liu, Yugui Xu, Dongxu Chen, Junjie Zhang, Ao Zhang, Xianguang Bai
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Li Liu

    Medical College, Pingdingshan University, Pingdingshan 467000, China
  • Yugui Xu

    Medical College, Pingdingshan University, Pingdingshan 467000, China
  • Dongxu Chen

    Medical College, Pingdingshan University, Pingdingshan 467000, China
  • Junjie Zhang

    Medical College, Pingdingshan University, Pingdingshan 467000, China
  • Ao Zhang

    Medical College, Pingdingshan University, Pingdingshan 467000, China
  • Xianguang Bai

    Medical College, Pingdingshan University, Pingdingshan 467000, China

Received: 31 October 2025; Revised: 4 December 2025; Accepted: 17 December 2025; Published: 25 February 2026

Ulcerative colitis (UC) is an immune-mediated inflammatory disease characterized by excessive pro-inflammatory cytokine activity and impaired immune regulation. Fecal microbiota transplantation (FMT) has emerged as a microbiome-based immunotherapeutic approach, yet its effects on systemic immune responses in UC remain incompletely understood. This study examined the immunomodulatory impact of FMT in a dextran sulfate sodium (DSS)–induced murine model of colitis. Forty-five male C57BL/6 mice were randomly assigned to control, DSS model, and FMT-treated groups (n = 15 per group). Colitis was induced with 3% DSS for seven days, followed by a seven-day intragastric administration of fecal suspension in the FMT group. Clinical disease activity, gross colonic morphology, and serum cytokine levels were assessed. DSS exposure resulted in pronounced colitis, evidenced by weight loss, elevated disease activity index scores, and macroscopic colonic injury. FMT significantly alleviated disease severity, improved body weight recovery, reduced disease activity, and partially restored colon length. Furthermore, FMT markedly reduced circulating pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) while increasing the levels of anti-inflammatory cytokines IL-4 and IL-10 (all p < 0.01). These findings suggest that FMT attenuates DSS-induced colitis and promotes a systemic shift toward an anti-inflammatory immune profile. Study limitations include the absence of quantitative histopathological scoring and immune-cell phenotyping. Further mechanistic studies are warranted to elucidate the immunological pathways underlying FMT-mediated protection in UC.

Keywords:

Fecal Microbiota Transplantation Ulcerative Colitis Inflammatory Cytokines Immune Regulation Gut Microbiota

References

  1. Shi, R.; Li, J.X.; Shen, H.; et al. Expert consensus on the diagnosis and treatment of ulcerative colitis in traditional Chinese medicine (2023). Chin. J. Tradit. Chin. Med. 2024, 39, 288–296. Available online: https://kns.cnki.net/kcms2/article/abstract?v=hyKDWyHWvTv1aVeBRNaBFZOL4-AXEhx_Okq5RNfzpqX0VGaYxLosCb4tRSrjf5ko8F_Pm3Tgn6y-pb75P8CZzAlKkWERCMUmgOHbWaHR5KwYYjPBtbniGQwfhhe7jhNavVJxXGu1J0JzhBDIBIVjC-tIKAJJ5e8ZteTPj9S22MO2fDf6G0800g==&uniplatform=NZKPT&language=CHS (in Chinese)
  2. Ordás, I.; Eckmann, L.; Talamini, M.; et al. Ulcerative colitis. Lancet 2012, 380, 1606–1619. DOI: https://doi.org/10.1016/S0140-6736(12)60150-0
  3. Voelker, R. What is Ulcerative Colitis? JAMA 2024, 331, 716. DOI: https://doi.org/10.1001/jama.2023.23814
  4. Liang, X.; Yin, F.; Zhang, X. Interpretation of the consensus on diagnosis and management of inflammatory bowel disease (Beijing, 2018) from the perspective of diagnosis of ulcerative colitis. Clin. Focus 2018, 33, 987–990. Available online: https://kns.cnki.net/kcms2/article/abstract?v=hyKDWyHWvTt9HoZPsldGx86_TCCESPeUboqMK03VgyCCztzZZPDZhCF_w0ULxNU5yrn1VrY9mltYdX3jAQNHmxypun3oEV5PtcZNdf99ijycyLgcuCaZsy-QEwxDs08B_QcT6DP1TLJB81f7RuyinpRQ-dDsC3c7iRC9kL3zIul8FpVuacdO6w==&uniplatform=NZKPT&language=CHS (in Chinese)
  5. Yamamoto-Furusho, J.K.; Gutierrez-Herrera, F.D. Molecular mechanisms and clinical aspects of colitis-associated cancer in ulcerative colitis. Cells 2025, 14, 162. DOI: https://doi.org/10.3390/cells14030162
  6. Du, L.; Ha, C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol. Clin. North Am. 2020, 49, 643–654. DOI: https://doi.org/10.1016/j.gtc.2020.07.005
  7. Kobayashi, T.; Siegmund, B.; Le Berre, C.; et al. Ulcerative colitis. Nat. Rev. Dis. Primers 2020, 6, 74. DOI: https://doi.org/10.1038/s41572-020-0205-x
  8. Zhang, S.; Zhong, R.; Tang, S.; et al. Metabolic regulation of the Th17/Treg balance in inflammatory bowel disease. Pharmacol. Res. 2024, 203, 107184. DOI: https://doi.org/10.1016/j.phrs.2024.107184
  9. Long, Y.; Xia, C.; Zheng, X.; et al. Functional alterations in colonic CD4⁺ T and regulatory T cells drive immune imbalance in ulcerative colitis. Immunol. Lett. 2025, 275, 107010. DOI: https://doi.org/10.1016/j.imlet.2025.107010
  10. Ma, Z.; Wang, Z.; Cao, J.; et al. Regulatory roles of intestinal CD4 T cells in inflammation and their modulation by the intestinal microbiota. Gut Microbes 2025, 17, 2560019. DOI: https://doi.org/10.1080/19490976.2025.2560019
  11. Salvatori, S.; Marafini, I.; Fonsi, A.; et al. Advanced therapies targeting IL-23: Clinical outcomes in ulcerative colitis. Expert Opin. Biol. Ther. 2025, 25, 873–885. DOI: https://doi.org/10.1080/14712598.2025.2539423
  12. Patik, I.; Redhu, N.S.; Eran, A.; et al. The IL-10 receptor inhibits cell extrinsic signals necessary for STAT1-dependent macrophage accumulation during colitis. Mucosal Immunol. 2023, 16, 233–249. DOI: https://doi.org/10.1016/j.mucimm.2023.02.006
  13. Kou, R.; Guo, Y.; Qin, Z.; et al. Systemic dysregulation of the gut microenvironment plays a pivotal role in the onset and progression of inflammatory bowel disease. Front. Immunol. 2025, 16, 1661386. DOI: https://doi.org/10.3389/fimmu.2025.1661386
  14. Zou, L.E.; Yang, Y.N.; Zhan, J.; et al. Gut microbiota-based discovery of Houttuyniae Herba as a novel prebiotic of Bacteroides thetaiotaomicron with anti-colitis activity. Biomed. Pharmacother. 2024, 172, 116302. DOI: https://doi.org/10.1016/j.biopha.2024.116302
  15. Kennedy, J.M.; De Silva, A.; Walton, G.E.; et al. A review on the use of prebiotics in ulcerative colitis. Trends Microbiol. 2024, 32, 507–515. DOI: https://doi.org/10.1016/j.tim.2023.11.007
  16. Dalal, R.; Sadhu, S.; Batra, A.; et al. Gut commensals-derived succinate impels colonic inflammation in ulcerative colitis. NPJ Biofilms Microbiomes 2025, 11, 44. DOI: https://doi.org/10.1038/s41522-025-00672-3
  17. Yan, S.; Chang, J.; Hao, X.; et al. Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora. Phytomedicine 2022, 102, 154217. DOI: https://doi.org/10.1016/j.phymed.2022.154217
  18. Liu, Y.J.; Tang, B.; Wang, F.C.; et al. Parthenolide ameliorates colon inflammation through regulating Treg/Th17 balance in a gut microbiota-dependent manner. Theranostics 2020, 10, 5225–5241. DOI: https://doi.org/10.7150/thno.43716
  19. Letz, P.; Huber, S.; Velasquez, L.N. Crosstalk between the microbiota and intestinal dendritic cells in IBD. Semin. Immunopathol. 2025, 47, 37. DOI: https://doi.org/10.1007/s00281-025-01062-9
  20. Abbas, A.; Di Fonzo, D.M.P.; Wetwittayakhlang, P.; et al. Management of ulcerative colitis: where are we at and where are we heading? Expert Rev. Gastroenterol. Hepatol. 2024, 18, 567–574. DOI: https://doi.org/10.1080/17474124.2024.2422370
  21. Sutanto, H.; Elisa, E.; Rachma, B.; et al. Gut microbiome modulation in allergy treatment: the role of fecal microbiota transplantation. Am. J. Med. 2025, in press. DOI: https://doi.org/10.1016/j.amjmed.2025.01.005
  22. Fanizzi, F.; D'Amico, F.; Zanotelli Bombassaro, I.; et al. The role of fecal microbiota transplantation in IBD. Microorganisms 2024, 12, 1755. DOI: https://doi.org/10.3390/microorganisms12091755
  23. Hemachandra, S.; Rathnayake, S.N.; Jayamaha, A.A.; et al. Fecal microbiota transplantation as an alternative method in the treatment of obesity. Cureus 2025, 17, e76858. DOI: https://doi.org/10.7759/cureus.76858
  24. Ciccia, F.; Gandolfo, S. Will fecal microbiota transplantation eventually be an effective therapeutic strategy for systemic lupus erythematosus? Clin. Immunol. 2022, 242, 109096. DOI: https://doi.org/10.1016/j.clim.2022.109096
  25. Zhang, L.; Ma, X.; Liu, P.; et al. Treatment and mechanism of fecal microbiota transplantation in mice with experimentally induced ulcerative colitis. Exp. Biol. Med. 2021, 246, 1563–1575. DOI: https://doi.org/10.1177/15353702211006044
  26. Wang, J.; Zhang, C.; Guo, C.; et al. Chitosan ameliorates DSS-induced ulcerative colitis mice by enhancing intestinal barrier function and improving microflora. Int. J. Mol. Sci. 2019, 20, 5751. DOI: https://doi.org/10.3390/ijms20225751
  27. Wen, X.; Wang, H.G.; Zhang, M.N.; et al. Fecal microbiota transplantation ameliorates experimental colitis gut microbiota and T-cell modulation. World J. Gastroenterol. 2021, 27, 2834–2849. DOI: https://doi.org/10.3748/wjg.v27.i21.2834
  28. Huang, C.; Mei, Q.; Lou, L.; et al. Ulcerative colitis in response to fecal microbiota transplantation via modulation of gut microbiota and Th17/Treg cell balance. Cells 2022, 11, 1851. DOI: https://doi.org/10.3390/cells11111851
  29. Hu, Y.; Tang, J.; Xie, Y.; et al. Gegen Qinlian decoction ameliorates TNBS-induced ulcerative colitis by regulating Th2/Th1 and Tregs/Th17 cell balance, inhibiting NLRP3 inflammasome activation and reshaping gut microbiota. J. Ethnopharmacol. 2024, 328, 117956. DOI: https://doi.org/10.1016/j.jep.2024.117956
  30. Borody, T.; Wettstein, A.; Campbell, J.; et al. Fecal microbiota transplantation in ulcerative colitis: review of 24 years experience. Am. J. Gastroenterol. 2012, 107, S665.
  31. Paramsothy, S.; Kamm, M.A.; Kaakoush, N.O.; et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017, 389, 1218–1228.
  32. Sun, L.L.; Xue, Q. Effects of fecal microbiota transplantation combined with sulfasalazine on serum inflammatory factors and T cell subsets in patients with ulcerative colitis. Clin. Transfus. Lab. Med. 2021, 23, 497–501. Available online: http://www.lcsxyjy.com/CN/10.3969/j.issn.1671-2587.2021.04.019 (in Chinese)
  33. Okayasu, I.; Hatakeyama, S.; Yamada, M.; et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98, 694–702.
  34. Le Berre, C.; Honap, S.; Peyrin-Biroulet, L. Ulcerative colitis. Lancet 2023, 402, 571–584. DOI: https://doi.org/10.1016/S0140-6736(23)00966-2
  35. de Oliveira, N.M.T.; Schneider, V.S.; Bueno, L.R.; et al. CPW partially attenuates DSS-induced ulcerative colitis in mice. Food Res. Int. 2023, 173, 113334. DOI: https://doi.org/10.1016/j.foodres.2023.113334
  36. Gupta, M.; Mishra, V.; Gulati, M.; et al. Natural compounds as safe therapeutic options for ulcerative colitis. Inflammopharmacology 2022, 30, 397–434. DOI: https://doi.org/10.1007/s10787-022-00931-1
  37. Zhou, J.; Zhou, Z.; Ji, P.; et al. Effect of fecal microbiota transplantation on experimental colitis in mice. Exp. Ther. Med. 2019, 17, 2581–2586. DOI: https://doi.org/10.3892/etm.2019.7263
  38. Kałużna, A.; Olczyk, P.; Komosińska-Vassev, K. The role of innate and adaptive immune cells in the pathogenesis and development of the inflammatory response in ulcerative colitis. J. Clin. Med. 2022, 11, 400. DOI: https://doi.org/10.3390/jcm11020400
  39. Liu, A.; Liang, X.; Wang, W.; et al. Human umbilical cord mesenchymal stem cells ameliorate colon inflammation via modulation of gut microbiota-SCFAs-immune axis. Stem Cell Res. Ther. 2023, 14, 271. DOI: https://doi.org/10.1186/s13287-023-03471-9
  40. Wei, Y.Y.; Fan, Y.M.; Ga, Y.; et al. Shaoyao decoction attenuates DSS-induced ulcerative colitis, macrophage and NLRP3 inflammasome activation through the MKP1/NF-κB pathway. Phytomedicine 2021, 92, 153743. DOI: https://doi.org/10.1016/j.phymed.2021.153743
  41. Qiu, X.; Luo, W.; Li, H.; et al. A traditional Chinese medicine, Zhenqi Granule, potentially alleviates dextran sulfate sodium-induced mouse colitis symptoms. Biology 2024, 13, 427. DOI: https://doi.org/10.3390/biology13060427
  42. Wu, H.; Tu, S.; Zhuo, Z.; et al. Investigating the mechanisms of bisdemethoxycurcumin in ulcerative colitis: network pharmacology and experimental verification. Molecules 2022, 28, 68. DOI: https://doi.org/10.3390/molecules28010068
  43. Tang, X.Y. Protective Effects and Mechanisms of Fecal Microbiota Transplantation on Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. PhD Thesis, Henan University, Kaifeng, China, 2019. Available online: https://kns.cnki.net/kcms2/article/abstract?v=hyKDWyHWvTuBO89B362ktC2IVzNkJcmUoGt7onLOBxhcrpWkhNjcpqpJimLZstfBbdD57viPy92pOR-0znw8iPxTXY6ObhnS60nNwq3VyPAFLmzu5lB8R42pDG2O3tqS4alAg2WCQASGXokP4Sn1G3JiO4zpHEDjdD961SV-9pa1BVHDaLnzdAVDYThhl5i2&uniplatform=NZKPT&language=CHS (in Chinese)
  44. Wang, Z.; Liu, T.; Liu, L.; et al. Lactobacillus vaginalis alleviates DSS-induced colitis by regulating the gut microbiota and increasing the production of 3-indoleacrylic acid. Pharmacol. Res. 2025, 213, 107663. DOI: https://doi.org/10.1016/j.phrs.2025.107663
  45. Morshedbak, M.; Rahimi, K.; Tabandeh, M.R. Effect of fecal microbiota transplantation on ulcerative colitis model in rats: the gut-brain axis. Heliyon 2025, 11, e42430. DOI: https://doi.org/10.1016/j.heliyon.2025.e42430
  46. Xu, N.; Bai, X.; Cao, X.; et al. Changes in intestinal microbiota and correlation with TLRs in ulcerative colitis in the coastal area of northern China. Microb. Pathog. 2021, 150, 104707. DOI: https://doi.org/10.1016/j.micpath.2020.104707
  47. Liu, C.; Wang, H.; Han, L.; et al. Targeting P2Y14R protects against necroptosis of intestinal epithelial cells through PKA/CREB/RIPK1 axis in ulcerative colitis. Nat. Commun. 2024, 15, 2083. DOI: https://doi.org/10.1038/s41467-024-46365-x
  48. Huang, Y.; Ma, Z.; Xu, X.; et al. Mechanism of morbidity based on ulcerative colitis: a review of traditional Chinese medicine treatment of ulcerative colitis. Int. J. Gen. Med. 2025, 18, 5811–5829. DOI: https://doi.org/10.2147/IJGM.S532534
  49. Yu, F.; Wang, X.; Ren, H.; et al. Lactobacillus paracasei Jlus66 relieves DSS-induced ulcerative colitis in a murine model by maintaining intestinal barrier integrity, inhibiting inflammation, and improving intestinal microbiota structure. Eur. J. Nutr. 2024, 63, 2185–2197. DOI: https://doi.org/10.1007/s00394-024-03419-6
  50. Ishihara, S.; Sato, T.; Fujikado, N.; et al. Rap1 prevents colitogenic Th17 cell expansion and facilitates Treg cell differentiation and distal TCR signaling. Commun. Biol. 2022, 5, 206. DOI: https://doi.org/10.1038/s42003-022-03129-x
  51. Kapoor, K.; Eissa, N.; Tshikudi, D.; et al. Impact of intrarectal chromofungin treatment on dendritic cells-related markers in different immune compartments in colonic inflammatory conditions. World J. Gastroenterol. 2021, 27, 8138–8155. DOI: https://doi.org/10.3748/wjg.v27.i47.8138